The short version of Tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Fighting broke out over Aden International Airport on 19 March, with special forces loyal to ex-president Ali Abdullah Saleh attempting to seize the airport before they were defeated by troops and militiamen under orders from the Hadi administration. The following day, in an apparently unrelated incident, four suicide bombers detonated themselves in Sanaa mosques packed with Houthi congregants, killing at least 142. The Sunni Islamist group Islamic State of Iraq and the Levant's Yemen branch claimed responsibility. Hadi declared Aden to be Yemen's temporary capital on 21 March while Sanaa remains under Houthi control. The next day, Houthi forces advanced toward Aden, capturing key parts of Yemen's third-largest city, Taiz. They consolidated their grip on much of the south and seized much of Aden itself by early April.
Overview of all the structural information available in the PDB for UniProt: Q9UBU3 (Human Appetite-regulating hormone) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: Q9EQX0 (Mouse Appetite-regulating hormone) at the PDBe-KB.
Papaverine is also present in combinations of opium alkaloid salts such as papaveretum (Omnopon, Pantopon) and others, along with morphine, codeine, and in some cases noscapine and others in a percentage similar to that in opium, or modified for a given application. Papaverine is found as a contaminant in some heroin and can be used by forensic laboratories in heroin profiling to identify its source. The metabolites can also be found in the urine of heroin users, allowing street heroin to be distinguished from pharmaceutical diacetylmorphine.
Sources: en.wikipedia.org
===== MeSH D08.811.913.817 – sulfur group transferases (EC 2.8) ===== MeSH D08.811.913.817.200 – coenzyme a-transferases MeSH D08.811.913.817.400 – sulfotransferases MeSH D08.811.913.817.400.300 – aryl sulfotransferase MeSH D08.811.913.817.500 – sulfurtransferases MeSH D08.811.913.817.500.500 – thiosulfate sulfurtransferase
=== Jim Dycker === James "Jim" Dycker (Charlie Heaton) is an intrepid financial journalist at FinDigest who is investigating Tender. A former trader who suffered major losses in the collapse of FTX, Jim is now determined to revive his career by being the one to break the story on Tender's misconduct. He shares custody of an infant son with his colleague Elaine, who he impregnated during a one-night stand. At the start of series 4, Jim follows Tender executive assistant Hayley Clay to a club, and the two spend the night in her apartment while she is intoxicated; she is enraged when he reveals his identity to her the following morning. Before Hayley kicks him out, Jim encourages her to look into the mysterious circumstances surrounding her predecessor's exit from the company. Jim later gets in touch with Harper, who is running a short-only fund, and tips her off that Tender is a strong target, having discovered that they are continuing to illegally process porn and gambling payments out of Africa despite publicly distancing themselves from those sectors to pivot to banking. Jim's tip leads Harper on her own investigation, but Jim himself is forced to publish a heavily edited version of the story. Tender leadership conspires to silence Jim after his discoveries, with Yasmin enlisting Lord Norton to defame Jim in the press as colluding with short sellers, using photos of him meeting Harper. Furthermore, Hayley files a sexual assault complaint against Jim.
== See also == Baby Friendly Hospital Initiative Breastfeeding promotion Breastfeeding contraindications Haberman Feeder Infant formula International Code of Marketing of Breast-milk Substitutes List of bottle types, brands and companies
Sources: en.wikipedia.org
== Clinical importance == S. haemolyticus is the second-most clinically isolated CoNS (S. epidermidis is the first) and it is considered an important nosocomial pathogen. Human infections include: native valve endocarditis, sepsis, peritonitis, and urinary tract, wound, bone, and joint infections. Infrequent soft-tissue infections usually occur in immunocompromised patients. Like other CoNS, S. haemolyticus is often associated with the insertion of foreign bodies, such as prosthetic valves, cerebrospinal fluid shunts, orthopedic prostheses, and intravascular, urinary, and dialysis catheters. S. haemolyticus is multi-drug resistant and able to form biofilms, which makes infections especially difficult to treat.
== Occurrence == Chymosin is found in a wide range of tetrapods, although it is best known to be produced by ruminant animals in the lining of the abomasum. Chymosin is produced by gastric chief cells in newborn mammals to curdle the milk they ingest, allowing a longer residence in the bowels and better absorption. Non-ruminant species that produce chymosin include pigs, cats, seals, and chicks. One study reported finding a chymosin-like enzyme in some human infants, but others have failed to replicate this finding. Humans have a pseudogene for chymosin that does not generate a protein, found on chromosome 1. Humans have other proteins to digest milk, such as pepsin and lipase. In addition to the primate lineage leading up to humans, some other mammals have also lost the chymosin gene.
=== Healthcare === Talarico supports healthcare reform and universal healthcare as a human right. He supports making buy-in Medicare or a public health insurance option available to every American, calling his healthcare plan "Medicare for Y'all". In August 2026, Talarico unveiled a healthcare plan focused on breaking up vertically integrated healthcare companies, including pharmacy benefit managers, insurance companies, and hospital networks. The proposal included measures to increase transparency in pharmacy benefit manager pricing, encourage the development and approval of generic drugs, and cap out-of-pocket healthcare costs.
Denaturing gels are run under conditions that disrupt the natural structure of the analyte, causing it to unfold into a linear chain. Thus, the mobility of each macromolecule depends only on its linear length and its mass-to-charge ratio. Thus, the secondary, tertiary, and quaternary levels of biomolecular structure are disrupted, leaving only the primary structure to be analyzed. Nucleic acids are often denatured by including urea in the buffer, while proteins are denatured using sodium dodecyl sulfate, usually as part of the SDS-PAGE process. For full denaturation of proteins, it is also necessary to reduce the covalent disulfide bonds that stabilize their tertiary and quaternary structure, a method called reducing PAGE. Reducing conditions are usually maintained by the addition of beta-mercaptoethanol or dithiothreitol. For a general analysis of protein samples, reducing PAGE is the most common form of protein electrophoresis. Denaturing conditions are necessary for proper estimation of molecular weight of RNA. RNA is able to form more intramolecular interactions than DNA which may result in change of its electrophoretic mobility. Urea, DMSO and glyoxal are the most often used denaturing agents to disrupt RNA structure. Originally, highly toxic methylmercury hydroxide was often used in denaturing RNA electrophoresis, but it may be method of choice for some samples. Denaturing gel electrophoresis is used in the DNA and RNA banding pattern-based methods temperature gradient gel electrophoresis (TGGE) and denaturing gradient gel electrophoresis (DGGE).
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.